For instance, an ongoing phase I clinical trial (NCT04003649) is currently examining the safety and effectiveness of CAR‐γδ T cells that target the folate receptor alpha (FRα) antigen, with a focus on patients with solid tumors that have not responded to traditional treatments, such as ovarian and pancreatic cancers. The gene discussed is FOLR1; the disease is pancreatic neoplasm.